Table 1 Comparison of clinical and pathologic features between complete laparoscopic surgery group and laparoscopic converse to open surgery group
Complete laparoscopic surgery group N = 51 (72.9%) | Laparoscopic converse to open surgery group N = 19 (27.1%) | P value | |
|---|---|---|---|
mean value ± SD | |||
Age, years | 61.0(51.0,68.0) | 61.0(54.0,68.0) | 0.995 |
BMI, kg/m2 | 22.5(20.1,27.0) | 23.5(21.1,24.8) | 0.958 |
Tumor diameter, cm | 8.3(5.4,10.3) | 9.1(7.1,11.0) | 0.214 |
Albumin, g/L | 39.0(37.0,42.8) | 40.9(37.0,42.1) | 0.672 |
Total Protein, g/L | 69.0(66.0,74.0) | 71.0(67.0,73.0) | 0.376 |
Hemoglobin, g/L | 122.0(108.0,139.0) | 121.0(109.0,126.0) | 0.566 |
Pre-operative serum creatinine, μmol/L | 92.0(80.0,111.0) | 110.0(89.0,130.0) | 0.026 |
Serum creatinine 1 week after operation, μmol/L | 103.0(86.0,117.0) | 112.0(79.0,122.0) | 0.658 |
Hospital stay after operation, days | 7.0(5.0,10.0) | 9.0(8.0,12.0) | 0.008 |
Operative time,min | 311.0(219.0,464.0) | 374.0(343.0,495.0) | 0.017 |
Surgical bleeding volume,ml | 600.0(200.0,1500.0) | 1300.0(800.0,3000.0) | 0.020 |
Surgical blood transfusion volume,ml | 400.0(0.0,800.0) | 800.0(0.0,1600.0) | 0.087 |
Plasma transfusion volume,ml | 0.0(0.0,200.0) | 0.0(0.0, 0.0) | 0.699 |
N (%) | |||
Sex | |||
Male | 34(66.7%) | 18(94.7%) | 0.016 |
Female | 17(33.3%) | 1(5.3%) | |
Side | 0.214 | ||
Left | 16(31.4%) | 9(47.4%) | |
Right | 35(68.0%) | 10(52.6%) | |
American society of anesthesiologists score | 0.154 | ||
1 | 1(2.0%) | 2(10.5%) | |
2 | 44(86.3%) | 13(68.4%) | |
3 | 6(11.8%) | 4(21.1%) | |
Clinical symptoms | 0.427 | ||
No clinical symptoms | 14(27.5%) | 2(10.5%) | |
Local symptoms | 25(49.0%) | 10(52.6%) | |
Systemic symptoms | 6(11.8%) | 3(15.8%) | |
Both | 6(11.8%) | 4(21.1%) | |
cN stage | 0.975 | ||
cN0 | 19(37.3%) | 7(36.8%) | |
cN1 | 32(62.7%) | 12(63.2%) | |
cM stage | 0.938 | ||
cM0 | 29(56.9%) | 11(57.9%) | |
cM1 | 22(43.1%) | 8(42.1%) | |
Mayo classification | 0.146 | ||
I | 26(51.0%) | 5(26.3%) | |
II | 20(39.2%) | 10(52.6%) | |
III | 5(9.8%) | 4(21.1%) | |
IVC resection | 0.155 | ||
No | 45(88.2%) | 14(73.7%) | |
Yes | 6(11.8%) | 5(26.3%) | |
Pathology type | 0.155 | ||
Clear cell carcinoma | 45(88.2%) | 14(73.7%) | |
Non clear cell carcinoma | 6(11.8%) | 5(26.3%) | |
Nuclear classification | 0.856 | ||
2 | 16(31.4%) | 5(26.3%) | |
3 | 22(43.1%) | 8(42.1%) | |
4 | 13(25.5%) | 6(31.6%) | |
Rhabdoid differentiation | 0.334 | ||
No | 48(94.1%) | 16(84.2%) | |
Yes | 3(5.9%) | 3(15.8%) | |
Sarcomatoid differentiation | 1.000 | ||
No | 46(90.2%) | 18(94.7%) | |
Yes | 5(9.8%) | 1(5.3%) | |
Invasion of perirenal fat | 0.260 | ||
No | 37(72.5%) | 11(57.9%) | |
Yes | 14(27.5%) | 8(42.1%) | |
Postoperative complications | 0.902 | ||
No | 26(51.0%) | 10(52.6%) | |
Yes | 25(49.0%) | 9(47.4%) | |